IAP4 Rec'd PCT/PTO 19 DEC 2005

Docket No. 29888-5 CERTIFICATE OF MAILING I hereby certify that this paper is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop PCT, Commissioner for Patents, PO Box 1450, Alexandria, VA 223/3-1450 on QC. 16, 2005

PATENT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant:

Mallen Huang

Paper No.:

Serial No.:

10/551,804

Group Art Unit:

Filing Date:

September 30, 2005

Examiner:

For: Nucleotide Vaccine Composition

INFORMATION DISCLOSURE STATEMENT

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In accordance with the provisions of 37 C.F.R. 1.56 and 1.97-1.98, Applicants cite the references listed on the attached Form PTO-1449. Copies of the non-U.S. patent references are enclosed.

Since the present statement is submitted prior to a first Official Action, no statement or fee under 37 C.F.R. §1.97 is required (37 C.F.R. §1.97(b)(1)).

Please charge any fee required in connection with this Statement to Deposit Account 04-1133.

Respectfully submitted,

Holly D. Kozlowski Reg. No. 30.

Dinsmore & Shohl LLP 1900 Chemed Center 255 East Fifth Street Cincinnati, Ohio 45202

(513) 977-8568

1215772v1

9°. 2														
PTO FORM 4/92 Page 1 of 1														
LIST FOR	OF P APPL		IS AI I'S IN	FOF	UBLIC EMATI		NS	APPLIC FILING	Y DOCKET: 29888-5 LICANT: Mallen Huang NG DATE: September 30, 2005 :: Nucleotide Vaccine Composition			SERIAL NO.: 10/551,804 GROUP:		
		ι	NITE	ED ST	TATES	LETT	ERS	PATEN	г			•••		
Exr. Init.		DOCUMENT NUMBER							DATE	NAME		CLASS	SUB CLASS	
				_										
				_	-		_		-					
				├	-		-							
				-	 		\vdash			-				
				\vdash		_								
				\vdash										
		FOREIGN PATENT DOCUMENTS												
		DOCUMENT NUMBER							DATE	COUNTRY		CLASS	SUB CLASS	
/S.F./	aa	01	1	1	0	6	7		Feb. 15, 2001	PCT				
/S.F./	ab	00	5	4	8	3	9		Sept. 21, 2000	PCT				
S.F./	ac	96	0	0	2	5	5		Feb. 1, 1996	PCT				
_	_							-						
_				-			-						-	
							┢						 	
					<u> </u>		\vdash						 	
отн	ER AR	T (INC	LUD	ING A	AUTHO	OR, TI	LE I	DATE, PE	ERTINENT PAGE	S, ETC.)				
/S.F.	ac	Ruobing Wang et al, "Induction of Antigen-Specific Cytotoxic T Lymphocytes in Humans by a Malaria DNA Vaccine", Science, Vol. 282, October, 1988, pp. 476-480.												
/S.F./	ad	John J. Donnelly et al, "DNA Vaccines", Annu. Rev. Immunol., 1997, 15:617-48.												
/S.F.	ae	Sanjay Gurunathan et al, "DNA Vaccines: Immunology, Application, and Optimization", Annu. Rev. Immunol., 2000, 18:927-974.												
/S.F./	af	John M. Timmerman et al, "Dendritic Cell Vaccines for Cancer Immunotherapy", Annu. Rev. Med., 1999, 50:507-529.												
/S.F./	ag	Ching-Hsiang Hsu et al, "Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization", Nature Medicine, Volume 2, Number 5, May 1996, pp. 540-544.												
S.F./	ah	Ari Waisman et al, "Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity", Nature Medicine, Volume 2, Number 8,												
/C. F	ai	August 1996, pp. 899-905. Keiichi Kontani et al, "Novel vaccination protocol consisting of injecting MUC1 DNA and nonprimed dendritic cells at the same region greatly enhanced MUC1-specific antitumor immunity in a murine model", Cancer Gene												
/S.F.		Therapy", 2002, 9, 330, 337.												

DATE CONSIDERED EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1215802v1